NNC0638-0355: NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.
Placebo (NNC0638-0355): Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.
Study summary
The study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in your body, and what your body does to the study medicine. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) given as an injection under your skin. Which treatment the participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Key inclusion criteria
* Male or female.
* Age 18-55 years (both inclusive) at the time of signing the informed consent.
* BMI between 25.0 and 34.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Key exclusion criteria
* Known or suspected hypersensitivity to study intervention(s) or related products.
* Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
* HbA1c greater than or equal to 6.5 percentage (48 mmol/mol) at screening.
* Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:
1. Vitamin D (25-hydroxycholecalciferol) less than 12 ng/mL (30 nM) at screening
2. Parathyroid hormone (PTH) outside normal range at screening
3. Total calcium outside normal range at screening
Primary outcome measure(s)
Part A: Number of treatment emergent adverse events (TEAE) — From NNC0638-0355 administration (day 1) to completion of the end of study visit (6 weeks) Measured as Number of events
Part B,C,D and E : Number of treatment emergent adverse events (TEAE) — From first NNC0638-0355 administration (day 1) to completion of the end of study visit (20 weeks) Measured as Number of events
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.